Home > Oncology > ESMO 2020 > Melanoma > Immuno-combination therapy in metastatic melanoma

Immuno-combination therapy in metastatic melanoma


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ESMO 2020
Both immune checkpoint inhibitors and targeted therapy have improved the treatment outcomes for patients with unresectable or metastatic melanoma. However, many patients experience disease progression and, therefore, new treatment strategies are needed. Several combinations of targeted therapy and immunotherapy are tested. In COMBI-I, 532 patients with unresectable or metastatic BRAF-mutated melanoma were randomised 1:1 to treatment with the PD-1 inhibitor spartalizumab (440 mg every 4 weeks) plus dabrafenib (150 mg BID) and trametinib (2 mg every 4 weeks) – the “triplet” – or placebo plus dabrafenib and trametinib – the “doublet” [1]. Median progression-free survival (PFS) was 16.2 months in the triplet arm and 12.0 months in the doublet arm (HR 0.82; P=0.042). Estimated PFS rates at 12 months were 58% and 50%, respectively, and 44% and 36% at 24 months. Based on the statistical design of the study, with a significance threshold for PFS a...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on